Exopert
Exopert is a South Korean biotech company founded in 2018, dedicated to improving human health through advanced exosome-based diagnostics. The company's core mission is to enable early detection of serious diseases, including various cancers and brain conditions, through a simple blood test. Exopert leverages its proprietary platform to analyze the entire exosome, allowing for the recognition of even subtle differences in patients without symptoms. Their vision is to become a leading global company by making cancer screening more accessible and affordable, ultimately contributing to a healthier society. The company is actively pursuing R&D collaborations with renowned institutions like Johns Hopkins University and MD Anderson Cancer Center, and has achieved the 'New Excellent Technology (NET)' certification for its early cancer diagnostic platform.
Exopert
Exopert is a South Korean biotech company founded in 2018, dedicated to improving human health through advanced exosome-based diagnostics. The company's core mission is to enable early detection of serious diseases, including various cancers and brain conditions, through a simple blood test. Exopert leverages its proprietary platform to analyze the entire exosome, allowing for the recognition of even subtle differences in patients without symptoms. Their vision is to become a leading global company by making cancer screening more accessible and affordable, ultimately contributing to a healthier society. The company is actively pursuing R&D collaborations with renowned institutions like Johns Hopkins University and MD Anderson Cancer Center, and has achieved the 'New Excellent Technology (NET)' certification for its early cancer diagnostic platform.